Your browser doesn't support javascript.
loading
Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy.
Bao, Alicia; Barsky, Andrew R; Maxwell, Russell; Bekelman, Justin E; Both, Stefan; Christodouleas, John P; Deville, Curtiland; Fang, Penny; Tochner, Zelig A; Vapiwala, Neha.
Afiliação
  • Bao A; Ohio State College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Barsky AR; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Maxwell R; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Bekelman JE; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Both S; Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands.
  • Christodouleas JP; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Deville C; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA.
  • Fang P; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Tochner ZA; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Vapiwala N; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Int J Part Ther ; 8(4): 14-24, 2022.
Article em En | MEDLINE | ID: mdl-35530185
ABSTRACT

Purpose:

Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment.

Methods:

One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS.

Results:

The median length of follow-up was 8.3 years (range, 1.2-10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05).

Conclusion:

Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Part Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Int J Part Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
...